The present invention provides a method of efficiently producing an optically active 6-(3-aminopiperidin-1-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine derivative.

The optically active piperidine-3-carboxamide or a derivative thereof, which is obtained by subjecting 1,4,5,6-tetrahydropyridine-3-carboxamide or a derivative thereof to an asymmetric reduction in the presence of a catalyst, is used as an intermediate.

Provided are a ligand compound of Formula 1 having a novel structure, which shows high catalyst activity and high selectivity to 1-hexene and 1-octene, and may perform ethylene oligomerization with excellent efficiency, an organochromium compound, a catalyst composition comprising the organochromium compound and a method for oligomerizing ethylene using the same,

##STR00001## wherein all the variables are as described herein.

Disclosed herein are systems and methods for modifying selectivity of heterogenous catalytic reactions.

The present invention relates to a ligand compound, a catalyst system for ethylene oligomerization, and a method for ethylene oligomerization using the same. The catalyst system for ethylene oligomerization according to the present invention not only has excellent catalytic activity but also shows more improved liquid olefin selectivity, and enables more effective preparation of an alpha-olefin through the oligomerization of ethylene because it is particularly possible to control the selectivity to 1-hexene or 1-octene.

The present invention relates to the design and synthesis of a class of novel chiral phosphine ligand, 1,2-bis(diphenylphosphinoalkylamido)-1,2-disubstituted ethane, and use in asymmetric catalytic reactions, such as asymmetric catalytic synthesis of pyrazoline-5-one with a chiral quaternary carbon center, i.e., highly enantioselective synthesis of 3-methyl-4-benzyl-4-(2-butyl-2,3-butadienyl)pyrazoline-5-one by using 3-methyl-4-benzylpyrazoline-5-one and benzyl (2-butyl-2,3-butadienyl) carbonate with tris(dibenzylideneacetone)dipalladium-chloroform adduct and this novel ligand as catalysts. The ligand designed by this present invention has the following advantages: the structure is novel, the synthesis and enlarge are simple, the enantioselective control effect in the practical reaction is excellent, which has a broad application prospect in chiral catalysis.

Novel organic compounds comprising a substituted anthracene or acridine ligand are provided. In particular, the compound includes an anthracene ligand substituted at the 9 and 10 positions. The compound may be used in organic light emitting devices to provide devices having improved efficiency and lifetime. In particular, these compounds may be especially beneficial for use in blue-emitting OLEDs.

Molybdenum(0) coordination complexes comprising at least one cycloheptatriene ligand and optionally one or more neutral ligands which coordinate to the metal center by carbon, nitrogen or phosphorous are described. Methods for depositing molybdenum-containing films on a substrate are described. The substrate is exposed to a molybdenum precursor and a reactant to form the molybdenum-containing film (e.g., elemental molybdenum, molybdenum oxide, molybdenum carbide, molybdenum silicide, molybdenum nitride). The exposures can be sequential or simultaneous.

Processes to produce tunable mixtures of 1-hexene and 1-octene are described. The process includes contacting a mixture of a 1-hexene catalyst and a 1-octene catalyst with ethylene under conditions sufficient to produce a composition that includes a desired amount 1-hexene and 1-octene are described.

An organometallic compound represented by Formula 1 ##STR00001## wherein, M.sub.1 to M.sub.4 are each independently a first-row transition metal, a second-row transition metal, or a third-row transition metal; X.sub.1 and X.sub.2 are each independently C(R.sub.5)(R.sub.6), Si(R.sub.5)(R.sub.6), N(R.sub.5), O, S, Se, or Te; W.sub.1 to W.sub.4 are each independently N(R.sub.7)(R.sub.8), P(R.sub.7)(R.sub.8), S(R.sub.7), a C.sub.5-C.sub.60 carbocyclic group unsubstituted or substituted with at least one R.sub.10a, or a C.sub.1-C.sub.60 heterocyclic group unsubstituted or substituted with at least one R.sub.10a; L.sub.1 to L.sub.6 are each independently a C.sub.1-C.sub.30 alkylene group unsubstituted or substituted with at least one R.sub.10a, a C.sub.5-C.sub.60 carbocyclic group unsubstituted or substituted with at least one R.sub.10a, or a C.sub.1-C.sub.60 heterocyclic group unsubstituted or substituted with at least one R.sub.10a, a3 to a6 are each independently an integer from 0 to 3, and R.sub.1 to R.sub.8 and R.sub.10a in Formula 1 are as described herein.